On November 16, Twist Bioscience Corp fell 6.62% in Regular Trading, trading at $103.54/share, with turnover of $21.397 million.
The move aligns with continued market digestion of a post-earnings reset in growth expectations, alongside additional analyst target price reductions that have pressured sentiment.
Twist Bioscience Corp previously reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus, while fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, investors remained focused on signals that AI drug discovery-related growth could slow in fiscal 2027. More recently, analysts lowered price targets, including UBS to $120, after earlier cuts by Jefferies to $125 and Guggenheim to $150, reinforcing pressure on the shares.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments